Background: Epidemiological evidence has suggested an association between hepatitis C virus (HCV) infection and B-cell lymphoproliferation. We studied the prevalence of HCV infection in a series of de novo B-cell non-Hodgkin's lymphoma (B-NHL) cases and correlated virological findings with clinico-histological features.
Introduction
Hepatitis C virus (HCV) is a lymphotropic virus involved in the pathogenesis of various extrahepatic diseases [1] . It is now acknowledged that HCV represents a major etiologic agent of mixed cryoglobulinemia (MC) type II [1] , which is characterized by a low-grade B-cell clonal lymphoproliferative disorder, initially confined to bone marrow but then evolving into a more aggressive malignant lymphoma in about 10%-20% of patients several years after diagnosis [2] . Recent epidemiologic studies have also documented the presence of HCV infection in a statistically significant proportion of de novo B-cell non-Hodgkin's lymphomas (B-NHL), not complicating the course of MC type II, which suggests a wider pathogenetic role of this virus in the multistep pathogenesis of lymphoid tumors [3] [4] [5] [6] .
We studied a well characterized series of 157 cases of de novo B-NHL in order: I) to assess the prevalence of serologic and molecular markers of HCV infection; 2) to correlate virological findings with the clinico-histologic features of lymphoma patients.
Patients and methods
One hundred fifty-seven unselected patients (87 men and 70 women) with B-NHL referred to our Institution between January 1989 and August 1993, were included in the study. The median follow-up was 72 months, and the mean age at presenlation of the disease was 65 years (range . In all cases the diagnosis was established on the basis of the histological analysis of either a lymph node or bone marrow or other pathology tissue biopsy, and revised according to the R.E.A.L. Classification [7] . All of the NHL cases were subjected to standard immunophenotyping procedures as well as to Southern blot analysis of immunoglobulin (Ig) heavy and light chain genes, to confirm the B-cell lineage. The distribution of histologic types is reported in Table 1 . All of the patients included in the study were HIV-negative Italian-born heterosexuals with no history of parenteral exposure to blood products, or of drug or alcohol abuse. Cryocrit determinations were done and cryoglobulin composition was evaluated [2] . An accurate staging of the disease was determined in each case, according to the Ann Arbor system. After informed consent, a liver biopsy was performed in all HCV-positive patients and in patients with biochemical and/or clinical signs of chronic liver disease. In eight B-NHL patients (two with lymphoplasmacytoid, four with follicular center and two with marginal zone lymphomas) associated with HCV infection, recombinant interferon alpha (IFN-a) was administered at the dose of three million units (MU) three times a week for nine months. All patients with diffuse large B-cell lymphomas were treated with the CHOP regimen, except for eight patients who were treated with the ProMACECytaBOM regimen. All patients with mantle zone lymphomas were A 'wait-and-see' approach was taken in lymphoplasmacytoid and follicular center lymphomas of all patients over the age of 70 years, although chlorambucil was introduced whenever progression of the lymphoma was observed. Lymphoplasmacytoid and follicular center lymphomas were treated with the CHOP regimen in all patients below the age of 70 years. The presence of anti-HCV antibodies was investigated in serum samples by enzyme-linked immunosorbent assays (ELISA) and confirmed in all cases by the recombinant-based immunoblot assay (RIBA) [4] . Serologic assays were performed on the sera from 157 B-NHL. Seventeen patients with T-cell non-Hodgkin's lymphoma (T-NHL), 103 patients with plasma cell dyscrasias (PCD; 21 multiple myeloma. 12 Waldenstrom macroglobulinemia and 70 monoclonal gammopathies of undetermined significance), and 23 patients with Hodgkin"s disease, were also studied, as controls, for the presence of anti-HCV antibodies.
For all of the patients with anti-HCV antibodies, the presence of HCV RNA sequences was investigated by reverse transcriptase polymerase chain reaction (RT-PCR) for the 5' untranslated (UTR) region, in either the PBMCs, lymph nodes or other pathology tissues obtained from the B-XHL patients, as we reported elsewhere [4] . Technical precautions were taken to ensure the specificity and sensitivity of HCV RNA determination, as previously reported [4] .
Statistical analysis was performed with the Statistical Package for Social Science (SPSS) [8] , using the chi-square test and Fisher's exact test, when appropriate. In all analyses a /'-value of 0.05 or less was considered to indicate statistical significance. Survival curves were estimated by the life-table method. The log-rank test was used to assess the significance of differences between groups [9] .
Results
Anti-HCV antibodies were detected at diagnosis by ELISA assay in the serum of 35 of 157 patients with B-NHL (22.3%). All seropositives were confirmed by the RIBA test. Using RT-PCR for 5' UTR region, HCV RNA sequences were detected in uncultured peripheral blood mononuclear cells (PBMCs) as well as in the pathology tissue from the HCV seropositive lymphoma patients. Since the seroprevalence of HCV infection in the general population of our area is estimated as approximately l%-2% [10] , the association between HCV infection and B-NHL is statistically significant (P < 0.0001). Conversely, HCV infection was documented in only 1 of 17 T-NHL (5%, P = 0.3), in 10 of 103 PCD (9%, P = 0.6) and in one of 23 HD (4%, P -0.8) cases, confirming the lack of a significant association between HCV infection and other lymphoma types.
The prevalence of HCV infection in the different histopathological groups of B-NHL is reported in Table l .We could not document a statistically significant association between HCV infection and any of the B-NHL histologic types according to the R.E.A.L. Classification [7] , although HCV infection occurred more frequently in follicular center, marginal zone, and diffuse large-cell lymphoma types. In 19 of 35 patients (54%), the B-NHL appeared an average of 61 months (range 12-144 months) after the diagnosis of HCV infection, while in the other 16 patients HCV positivity was documented at the time of B-NHL diagnosis. None of the HCV-positive patients had previously been exposed to blood products (red cells, platelets, coagulation factors, and immunoglobulins) prior to the diagnosis of lymphoma. No source of infection could be established in these patients, as is the case in the majority of reported cases of HCV infection. All cases of B-NHL were investigated for the presence of cryoglobulins, although none of the patients presented clinical manifestations of cryoglobulinemia. We clinically documented asymptomatic cryoglobuiinemia in 10 HCV-positive B-NHL patients (28%), namely, cryoglobulinemia type I in one patient (with lymphoplasmacytoid lymphoma), type II in five patients (four with follicular center and one with marginal zone lymphomas) and type III in four patients (two with follicular center and two with marginal zone lymphomas). Of the HCV-negative B-NHL patients, only three (two with follicular center and one with mantle cell lymphomas) manifested a clinically asymptomatic cryoglobulinemia type III. The association of asymptomatic cryoglobulinemia with HCV infection in B-NHL patients was definitely statistically significant (P < 0.0001). The clinico-epidemiological characteristics of all B-NHL patients are reported in Table 1 . No marked differences regarding stage, symptoms, or bone marrow involvement were observed between HCV-positive and -negative B-NHL patients, except for male/ female ratio. Of the HCV-positive B-NHL patients, four had autoimmune manifestations, namely, Sjogren's syndrome in two patients with marginal zone lymphoma, Hashimoto's thyroiditis in one patient with marginal zone lymphoma and idiopathic thrombocytopenic purpura in one patient with follicular center lymphoma. Abnormal serum levels of alanino-aminotransferase (ALT) were found in 20 of 35 HCV-positive (57%), and in five of 122 HCV-negative (4%) B-NHL patients. All HCV-positive B-NHL patients underwent liver biopsy, which showed chronic liver disease in 32 (91%) and lymphomatous involvement of the liver in six (17%) patients, while liver histology showed minimal changes in three patients. The median survival time was 48 months for HCV-positive and 52 months for HCV-negative B-NHL patients (Figure 1 ). The main causes of death were lymphoma complications in both HCV-positive and HCV-negative B-NHL patients. Only two HCV-positive patients died of severe liver dysfunction, although the concomitant severe progression of lymphoma, resistant to treatment, was documented in both patients. Interruption of chemotherapy regimens was not required in any of the HCV-positive patients for liver-related causes.
Discussion
Our study shows a high prevalence of HCV infection in patients with B-NHL which is not associated with MC type II, consistent with recent epidemiologic studies from Italy [3] [4] [5] [6] , Japan [11] and the US [12] . In contrast to these findings, two different studies from the UK failed to detect a correlation between HCV and B-lymphoid neoplasias, but the number of patients studied was small and ethnic/geographic factors could account for such discrepancy, given the very low prevalence of HCV infection among the normal UK population, which is, for example, 100 times less than that in Italy [13, 14] . Two recent Italian studies showed a strict association between HCV infection and only one histologic type, namely, lymphoplasmacytoid lymphoma, but it should be noted that a significant proportion of the lymphoma patients studied in both series showed an unexpectedly high prevalence of associated, clinically symptomatic, MC type II [15, 16] . On the other hand, the histologic substrate of MC type II, when detectable, corresponds to that of the lymphoplasmacytoid lymphoma. Thus, the reported highest prevalence of HCV infection in lymphoplasmacytoid lymphoma is expected, as it mirrors the well-known high prevalence of HCV infection in MC type II. In our series of B-NHL patients we could not identify cases of associated, clinically symptomatic, MC type II, although the presence of clinically asymptomatic cryoglobulins was observed and found to be higher in HCV-positive than in HCV-negative B-NHL patients. If we exclude patients with MC type II-associated lymphoma from the study, it is seen that among HCV-positive de novo B-NHL cases the most frequent histologic types are follicular center, marginal zone, and diffuse large-cell lymphoma. This finding suggests a possible influence of HCV on distinct subsets of B lymphocytes, other than the immunoglobulin (Ig) Mk producing B-cell subset, which is acknowledged to be at the origin of MC type II and associated lymphoplasmacytoid lymphoma.
Identification of a serologic response to a virus years before the occurrence of a tumor is considered one of the most important parameters for the suggestion of a viral etiology for such a tumor. For example, the detection of antibodies to EBV in patients with nasopharyngeal carcinoma, Burkitt's lymphoma and Hodgkin's disease before the occurrence of such diseases provided the first evidence of this etiologic relationship [17] . Similarly, we can demonstrate that the presence of serologic markers of HCV infection preceded the occurrence of B-NHL in more than one-half of the cases in our series. Thus, the proposed involvement of HCV in the pathogenesis of de novo B-NHL is largely based on epidemiologic studies showing: 1) a higher prevalence of HCV infection in B-NHL than in other lymphomas (T-NHL, PCD and HD) and in the normal population of the same geographic area; 2) a possible association with specific histologic types of B-NHL; 3) the occurrence of HCV infection years before the diagnosis of B-NHL; and 4) the identification of the viral genome within the lymphomatous lesions.
The few available in vitro studies have documented a transforming potential of some HCV genes [18, 19] , but given the inability of the virus to integrate into the infected host cell, the possible oncogenetic mechanisms are largely speculative, although a direct transforming role of HCV in the lymphoproliferation process seems unlikely. It has been proposed that the pathogenetic role of HCV is represented by indirect effects of chronic infection of lymphocytes, possibly representing the viral reservoir. Moreover, taking advantage of its tropism for epithelial cells in vivo, HCV may act as an exogenous antigenic stimulus, able to sustain B-cell lymphoproliferation in either a T-cell-dependent or -independent process, at least in the subgroup of lymphomas of mucosa-associated lymphoid tissue (MALT) type [20, 21] . It may be hypothesized that the virus, in combination with other factors, i.e., genetic, infectious and/or environmental, may produce, among variable host responses, a proliferative response of lymphoid elements to HCV antigens. We recently reported a distribution of HCV genotypes in B-NHL patients which is different from that in patients with long-term hemodialysis and chronic liver disease, suggesting the possible influence of HCV-related factors, namely, of specific viral genotypes, in triggering the proliferative response of preferential B-cell subsets [22] .
Finally, HCV-related disease did not affect the survival in our series of B-NHL patients. The possibility is raised that the rare occurrence of severe liver dysfunction in HCV-infected patients with B-NHL treated with chemotherapy is partly related to the fact that genotype lb-II, generally associated with a more severe liver disease, has an unexpectedly lower prevalence in these patients, as we reported elsewhere [22] . On the other hand, HCV infection may induce liver injury through autoimmune mechanisms [23] , as was recently underscored by the reported occurrence of fulminant hepatitis upon withdrawal of chemotherapy in two carriers of HCV infection also affected with lymphoma [24] . Thus, chemotherapy and/or high-dose prednisone, commonly administered to these B-NHL patients, may even exert a beneficial effect in controlling HCV-related chronic liver disease, at least in some patients. Based on its lymphotropism, HCV may have an impact on clinical outcome and prognosis of B-NHL patients through mechanisms other than liver injury. Further studies are now required on larger series of cases stratified for the different prognostic factors, except for HCV infection. Only such studies can clarify whether HCV infection indeed comprises an independent prognostic factor in different histologic types of B-NHL.
